ATAI News and Press, ATAI Life Sciences N.V. From 03/24/23

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditions Continued operational progress on robust clinical pipeline, with multiple phase 1 and phase 2 proof-of-...

A growing body of scientific literature has revealed that psychedelics have the potential to treat a variety of mental disorders. Drugs such as ketamine, ecstasy (MDMA) and psilocybin have shown in clinical studies that they are capable of treating psychiatric disorders , including treatment-res...

Psychedelics have been enjoying increased media attention in recent years due to their therapeutic potential. Research and clinical studies on the applications of hallucinogenic drugs has revealed that they are capable of treating the symptoms of mental health conditions such as major depressi...

2023-03-06 12:27:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughl...

2023-03-06 07:44:23 ET Atai Life Sciences ( NASDAQ: ATAI ) has reduced its workforce by ~30% as part of a strategic review, the company said while providing other clinical and corporate updates. Atai noted that the decision to reduce workforce was taken after a strategi...

RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophrenia GRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical development COMP360: Recently announced acceleration o...

Psychedelics are poised to revolutionize the psychiatric industry over the next couple of decades. In the midst of a global mental health crisis that has affected more than a billion people around the world, researchers have been working to develop psychedelic-assisted therapies to treat a my...

NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. De...

Summary There have been some exciting developments in the research around the medicinal potential of psychedelic compounds. Despite a potential opportunity for disruption, investors should keenly understand the unique risks to biotechnology plays before investing in the space. Given...

In just a few short years, psychedelics have presented themselves as a potential alternative to pharmaceutical mental health therapies. Research into hallucinogenic drugs has revealed that they are capable of alleviating the symptoms of mental disorders, such as treatment-resistant depression...